Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Borhane, Slama"'
Autor:
Robin Noel, Christophe Zemmour, Catalina Montes de Oca, Nawel Belmecheri, Thérèse Aurran-Schleinitz, Diane Coso, Leonor Lopez Almeida, Lénaïg Mescam, Norbert Vey, Jean Sébastien Bladé, Borhane Slama, Reda Bouabdallah, Jean-Marc Schiano de Colella
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTRelapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treat
Externí odkaz:
https://doaj.org/article/5faa13572f5842b490fbc2b2496eba87
Autor:
Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, Kamel Laribi
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 45-54 (2023)
Abstract The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in p
Externí odkaz:
https://doaj.org/article/fe50306f84f445cd873e4e8c3079f682
Autor:
Caroline Dartigeas, Borhane Slama, Margaret Doyle, Christoph Tapprich, Claire Albrecht, Sandrine Dupuis, Robert Wapenaar, Charlotte Schmidt-Hieber, Veronique Leblond
Publikováno v:
Clinical Hematology International, Vol 4, Iss 3, Pp 65-74 (2022)
Abstract The FIRE study investigated the real-world effectiveness and safety of ibrutinib in prospectively observed patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in France. Patients w
Externí odkaz:
https://doaj.org/article/a1c7626872d6438d82dd956185a4915a
Autor:
Pilar Dutari, Tantrantan Leonce Adjoumani, Safia Chebrek, Thierry Takam, Hacene Zerazhi, Jesica Elizabe Weber Vidoret, Borhane Slama
Publikováno v:
HemaSphere, Vol 7, p e4666516 (2023)
Externí odkaz:
https://doaj.org/article/51f63c57c603402dbd553178627f2a74
Autor:
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Mahéo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frédérique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Hervé Avet-Loiseau, Jill Corre
Publikováno v:
Blood. 141:1308-1315
Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears to be the second worst abnormality after del(17p).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66fc2af4eb8ace0f9a991bfe8065a525
https://doi.org/10.1182/blood.2022017863
https://doi.org/10.1182/blood.2022017863
Autor:
Madeleine Akrich, Églantine Armand-Rastano, Nathalie Bajos, Janine Barbot, François Beck, Sylvain Bertschy, Linda Cambon, Alice Desclaux, Tania Dos Santos, Cécile Durand, Cécile Fournier, Delphine Gardey, Sébastien Gardon, Amandine Gautier, Maud Gelly, Gabriel Girard, Baptiste Godrie, Moritz Hunsmann, Yves-Gabriel Kerisit, Thierry Lang, Brice Laurent, Solenne Larrère, Borhane Slama, Judith Wolf
Publikováno v:
Sciences Sociales et Santé. 40:69-106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd55b6c14d08702802474b67117c9c0f
https://doi.org/10.1684/sss.2022.0238
https://doi.org/10.1684/sss.2022.0238
Autor:
Marlijn Hoeks, Ge Yu, Saskia Langemeijer, Simon Crouch, Louise de Swart, Pierre Fenaux, Argiris Symeonidis, Jaroslav Čermák, Eva Hellström-Lindberg, Guillermo Sanz, Reinhard Stauder, Mette Skov Holm, Moshe Mittelman, Krzysztof Mądry, Luca Malcovati, Aurelia Tatic, Antonio Medina Almeida, Ulrich Germing, Aleksandar Savic, Njetočka Gredelj Šimec, Dominic Culligan, Raphael Itzykson, Agnes Guerci-Bresler, Borhane Slama, Jackie Droste, Corine van Marrewijk, Arjan van de Loosdrecht, Nicole Blijlevens, Marian van Kraaij, David Bowen, Theo de Witte, Alex Smith, on behalf of the EUMDS Registry Participants
Publikováno v:
Haematologica, Vol 105, Iss 3 (2020)
Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data
Externí odkaz:
https://doaj.org/article/9a10f74e758c4ead98bfef9a93cc5b72
Autor:
Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, Kamel Laribi
Publikováno v:
eJHaem. 4:45-54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8276eaa77d152d87e9f2c084ce2fce6
https://doi.org/10.1002/jha2.593
https://doi.org/10.1002/jha2.593
Autor:
Sophie Park, Olivier Kosmider, Frédéric Maloisel, Bernard Drenou, Nicolas Chapuis, Thibaud Lefebvre, Zoubida Karim, Hervé Puy, Anne Sophie Alary, Sarah Ducamp, Frédérique Verdier, Cécile Bouilloux, Alice Rousseau, Marie-Christine Jacob, Agathe Debliquis, Agnes Charpentier, Emmanuel Gyan, Bruno Anglaret, Cecile Leyronnas, Selim Corm, Borhane Slama, Stephane Cheze, Kamel Laribi, Shanti Amé, Christian Rose, Florence Lachenal, Andrea Toma, Gian Matteo Pica, Martin Carre, Frédéric Garban, Clara Mariette, Jean-Yves Cahn, Mathieu Meunier, Olivier Herault, Pierre Fenaux, Orianne Wagner-Ballon, Valerie Bardet, Francois Dreyfus, Michaela Fontenay
Publikováno v:
Haematologica, Vol 104, Iss 3 (2019)
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythro
Externí odkaz:
https://doaj.org/article/d465efe30d0a4795a3a8445ef181d7b6
Autor:
Guillaume Cartron, Emmanuel Bachy, Hervé Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj, Borhane Slama, Olivier Casasnovas, Roch Houot, Krimo Bouabdallah, David Sibon, Olivier Fitoussi, Nadine Morineau, Charles Herbaux, Thomas Gastinne, Luc-Matthieu Fornecker, Corinne Haioun, Vincent Launay, Carla Araujo, Omar Benbrahim, Laurence Sanhes, Remy Gressin, Hugo Gonzalez, Franck Morschhauser, David Ternant, Luc Xerri, Karin Tarte, Delphine Pranger
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment (TTNT) when compared with the watch and wait strategy for patients with low–tumor burden follicular lymphoma (FL). Prolonged rituximab maintenance did not prolong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7649764f7988251af924e03a3cb0a116
https://doi.org/10.1200/jco.22.02327
https://doi.org/10.1200/jco.22.02327